Symrise AG
Explore by topic
5-year stock timeline
2026-07-30 — H1 2026 results; accelerating organic growth; portfolio moves
Symrise reported H1 2026 results showing accelerating growth in Q2 and announced portfolio transactions: a binding offer for the Floral Concept acquisition and a signed agreement to divest the Terpene Ingredients business to Mutares SE & Co. An inaugural €400m share buyback program announced earlier in 2026 was active. [7][1]
Market perception shifted toward "ONE Symrise" execution and portfolio-sharpening. Investors emphasized margin expansion, cash conversion and active capital allocation (buyback and continued dividend increases) rather than pure top-line acceleration. The Floral Concept move was seen as selective premium naturals M&A to lift product mix; the terpene divestment signaled portfolio pruning. [7][1]
Organic sales growth accelerated to 4.5% in Q2 2026 (2.0% in H1 2026). Adjusted EBITDA reached €553m with an adjusted EBITDA margin of 21.8%. Adjusted Business Free Cash Flow margin was 13.7% of sales. [2][7]
2026-03-04 — FY 2025 results announced
Symrise published FY 2025 results and 2026 guidance ranges. Management highlighted record adjusted Business Free Cash Flow and announced capital allocation priorities including a €400m share buyback program and a proposed dividend increase. [6][9]
Investors framed Symrise as a cash-generative specialty-chemicals and ingredients compounder with disciplined M&A and shareholder returns. The emphasis on record BFCF and buyback supported a valuation narrative focused on cash returns and margin improvement. [6][9]
Group sales reached €4,929 million for FY 2025 with organic sales growth of 2.8%. Adjusted EBITDA margin was 21.9% and adjusted Business Free Cash Flow hit a record €780 million (15.8% BFCF margin). For 2026, the company guided to organic growth of 2.0–4.0%, adjusted EBITDA margin of 21.5–22.5%, and BFCF margin above 14%. [6][9]
2025-07-30 — H1 2025 results; Executive Board appointment
Symrise reported first-half 2025 results and appointed Michael Friede as Executive Board Member and President of the Scent & Care segment. [15]
Management changes in the Scent & Care segment were seen as strengthening go-to-market and product leadership in a core margin-contributing segment. H1 performance and leadership appointments reinforced the company's "growth with margin" message. [15]
2024 — Continued post-pandemic recovery; focus on premiumization and naturals
Symrise continued executing growth initiatives throughout 2024 with strategic emphasis on premium naturals, sustainability and innovation. Corporate materials highlighted investments and segment focus. [10]
Investor perception was that Symrise was transitioning from pandemic-recovery volatility into a steady compounder driven by premiumization (naturals, fragrances, taste & nutrition) and margin management. Sustainability and product-portfolio premiumization were recurring themes in investor communications. [10]
2023 — Post-COVID demand normalization; organic growth pressures and margin actions
Symrise reported results reflecting normalization after pandemic disruption and raw-material and cost pressures. Management emphasized efficiency measures and value-based pricing. [8][10]
Investors saw 2023 as a year of margin-defense and working-capital management rather than aggressive growth; the story leaned toward a resilient specialty-ingredients operator protecting profitability and cash. [8][10]
2022 — Strong recovery year with notable revenue growth
Symrise reported a significant rebound in 2022 sales and growth following pandemic-related weakness in prior periods. [8]
Market perception shifted back toward growth, with investors expecting cyclical end-markets (flavors, fragrances, personal care) to recover and drive revenue expansion. The company's M&A and R&D positioning were framed as support for a durable growth trajectory. [8]
2021 — Pandemic-year pressures; revenue weakness and margin sensitivity
Symrise's 2021 reporting reflected lingering impacts of COVID-19 on certain end markets (fragrances, out-of-home flavors), leading to uneven top-line performance and heightened investor focus on margin resilience and cost management. [8]
Investors viewed 2021 as a stress-test year — the company was fundamentally a specialty-ingredients compounder but exposed to shifts in consumer demand. Attention centered on management execution to restore growth and margins. [8]
Key risks and downside factors
Symrise AG supplies flavours, fragrances, cosmetic active ingredients, and functional ingredients to a concentrated market where a handful of large diversified players and numerous regional specialists compete. Its main public competitors are Givaudan, IFF (which includes DSM-Firmenich), Firmenich, and MANE. The company faces three persistent strategic pressures: competitive intensity, raw-material cost volatility, and the regulatory constraints on ingredient use, alongside the execution risk inherent in integrating acquisitions.
- Larger competitors—Givaudan, IFF/DSM-Firmenich, and MANE—hold advantages in scale, R&D spending, and customer access, creating sustained pressure on pricing and margins.
- Raw material and commodity price swings—spanning natural extracts, botanical supplies, and petrochemical-based aroma precursors—can compress gross margins and force companies to adjust pricing downstream.
- Regulatory constraints on fragrance and flavor ingredients—including EU REACH requirements, IFRA guidelines, FDA standards, and comparable jurisdictional rules—can necessitate product reformulations, elevate compliance expenses, or narrow the addressable market for finished goods.
- Acquisition and integration execution risk can affect earnings, cash flow, and credit metrics through challenges in realizing synergies, managing cultural integration, and handling increased debt [8], [3].
Competitive landscape
Symrise operates across flavors, fragrances, cosmetic active ingredients, and nutrition and health ingredients. Its competitors range from a handful of large global specialty-ingredients companies to numerous regional and private makers. The competitive landscape is shaped by a few large public peers that possess scale, broad R&D capabilities, and established global customer relationships. Raw-material and energy cost volatility present ongoing pressure, as do regulatory and compliance shifts affecting ingredient approvals. The company faces execution risks around acquisitions and integration, while broader market demand cycles and currency movements influence both margins and growth trajectories. Symrise's own disclosures identify climate, supply-chain, regulatory, and IT risks as potential material headwinds to EBIT under adverse scenarios.
| Company | Ticker |
|---|---|
| Givaudan | GIVN.SWX |
| IFF (International Flavors & Fragrances) | IFF.NYSE |
| Mane | MAN.PA |
Private competitors
- Firmenich & DSM combined businesses (note: DSM-Firmenich merger created a large private/global player in some jurisdictions prior to public listing changes)
- Regional/private flavor and fragrance houses and specialist startups (examples: Inolex — private or privately held entities in specialty cosmetics; numerous olfaction/biotech startups)
Get More Stock Analyses Like This
Receive hand-picked stock recommendations with detailed analyses every week
Start Free TrialPerformance Figures of Symrise AG
Relative Performance vs Benchmarks
| Period | Symrise AG | vs DAX | vs S&P 500 (SPY) |
|---|---|---|---|
| 1M | +2.09% | +5.42% | +0.68% |
| 3M | +3.59% | +3.50% | -0.31% |
| 6M | +27.40% | +21.78% | +12.16% |
| 1Y | +22.35% | +19.25% | +4.66% |
| 3Y | +6.74% | -58.34% | -81.34% |
| 5Y | -13.68% | -79.02% | -103.92% |
Get More Stock Analyses Like This
Receive hand-picked stock recommendations with detailed analyses every week
Start Free TrialHistorical valuation trends
How the company’s key valuation ratios (P/E, P/S, P/B and P/CF) have evolved over time compared to today.
| Period | P/E Ratio | P/S Ratio | P/B Ratio | P/CF Ratio |
|---|---|---|---|---|
| Current | 34.4 | 1.7 | 3.4 | 9.8 |
| 1Y ago | 27.6 | 2.1 | 2.8 | 11.6 |
| 3Y ago | 43.1 | 2.6 | 3.4 | 21.3 |
| 5Y ago | 30.2 | 2.9 | 4.9 | 20.2 |
Frequently Asked Questions
Where is the Symrise AG stock traded?
What does Symrise AG do?
What are the key metrics for SY1.XETRA?
How has Symrise AG's stock price performed?
How is SY1.XETRA valued?
Does SY1.XETRA pay dividends?
What are the key risks when investing in SY1.XETRA?
- Larger competitors—Givaudan, IFF/DSM-Firmenich, and MANE—hold advantages in scale, R&D spending, and customer access, creating sustained pressure on pricing and margins.
- Raw material and commodity price swings—spanning natural extracts, botanical supplies, and petrochemical-based aroma precursors—can compress gross margins and force companies to adjust pricing downstream.
- Regulatory constraints on fragrance and flavor ingredients—including EU REACH requirements, IFRA guidelines, FDA standards, and comparable jurisdictional rules—can necessitate product reformulations, elevate compliance expenses, or narrow the addressable market for finished goods.
- Acquisition and integration execution risk can affect earnings, cash flow, and credit metrics through challenges in realizing synergies, managing cultural integration, and handling increased debt [8, 3, 21].
Who are the main competitors of Symrise AG?
- Givaudan (GIVN.SWX)
- IFF (International Flavors & Fragrances) (IFF.NYSE)
- Mane (MAN.PA)
When does Symrise AG report earnings?
Key Metrics
Valuation Metrics
Profitability Metrics
Growth Metrics
Dividend history
Long-term record of paid dividends (amount per share and dividend yield at the time of payment).
| Year | Dividend | Yield at payment | Avg. yield |
|---|---|---|---|
| 2026 | 1.25 EUR | 1.65% | 1.25% |
| 2025 | 1.20 EUR | 1.14% | |
| 2024 | 1.10 EUR | 1.08% | |
| 2023 | 1.05 EUR | 0.97% | |
| 2022 | 1.02 EUR | 0.93% | |
| 2021 | 0.97 EUR | 0.89% | |
| 2020 | 0.95 EUR | 0.98% | |
| 2020 | 0.95 EUR | 1.02% | |
| 2019 | 0.90 EUR | 1.04% | |
| 2018 | 0.88 EUR | 1.23% | |
| 2017 | 0.85 EUR | 1.34% | |
| 2016 | 0.80 EUR | 1.40% | |
| 2015 | 0.75 EUR | 1.32% | |
| 2014 | 0.70 EUR | 1.84% | |
| 2013 | 0.65 EUR | 1.99% |
Earnings history & estimates
Historical earnings performance shows how consistently the company meets or exceeds analyst expectations. Forward estimates provide insight into expected profitability and growth trajectory.
Historical earnings performance
Upcoming earnings report
Analyst estimates for upcoming periods
Key financial figures
Selected income statement, balance sheet and cash flow figures. Annual and quarterly, based on reported IFRS/GAAP financials.
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | 4.93B | 5.00B | 4.73B | 4.62B | 3.83B |
| Operating income (EBIT) | 609.30M | 717.80M | 559.36M | 503.98M | 558.96M |
| Net income | 249.30M | 478.20M | 340.47M | 280.01M | 374.92M |
| Free cash flow | 521.05M | 667.49M | 449.31M | 109.94M | 347.40M |
| Total assets | 8.11B | 8.32B | 7.85B | 7.78B | 6.64B |
| Equity | 3.72B | 3.98B | 3.63B | 3.55B | 3.19B |
| Net debt | 1.60B | 1.84B | 2.17B | 2.23B | 1.35B |
PWP Leeway UG (haftungsbeschränkt)
